EHU064801
MISSION® esiRNA
targeting human HS6ST2
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
NACRES:
NA.51
UNSPSC Code:
41105324
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarledescription
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
ACATCACCATCCTCCGAGACCCAGTGTCCCGGTACTTGAGTGAGTGGAGGCATGTCCAGAGAGGGGCAACATGGAAAGCATCCCTGCATGTCTGCGATGGAAGGCCTCCAACCTCCGAAGAGCTGCCCAGCTGCTACACTGGCGATGACTGGTCTGGCTGCCCCCTCAAAGAGTTTATGGACTGTCCCTACAATCTAGCCAACAACCGCCAGGTGCGCATGCTCTCCGACCTGACCCTGGTAGGCTGCTACAACCTCTCTGTCATGCCTGAAAAGCAAAGAAACAAGGTCCTTCTGGAAAGTGCCAAGTCAAATCTGAAGCACATGGCGTTCTTCGGCCTCACTGAGTTTCAGCGGAAGACCCAATATCTGTTTGAGAAAACCTTCAACATGAACTTTATTTCGCCATTTACCCA
Ensembl | human accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
human ... HS6ST2(90161)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Clase de almacenamiento
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Jeanne L Theis et al.
eLife, 9 (2020-10-03)
Congenital heart diseases (CHDs), including hypoplastic left heart syndrome (HLHS), are genetically complex and poorly understood. Here, a multidisciplinary platform was established to functionally evaluate novel CHD gene candidates, based on whole-genome and iPSC RNA sequencing of a HLHS family-trio.